The presence of dominant follicles and corpora lutea does not perturb response to controlled ovarian stimulation in random start protocols.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
22 06 2020
22 06 2020
Historique:
received:
08
09
2019
accepted:
15
05
2020
entrez:
24
6
2020
pubmed:
24
6
2020
medline:
12
1
2021
Statut:
epublish
Résumé
The advent of random start protocols to shorten the time needed to store oocytes in women with malignancies has represented an important improvement in the field of fertility preservation. However, Randomized Controlled Trials are difficult to implement in this area and available evidence that supports this approach remains modest. To shed more light on this issue, we compared the follicular development between the ovary carrying the dominant follicle or the corpus luteum and the contralateral resting ovary in 90 women who underwent random start controlled ovarian stimulation (COS). In fact, ovarian response did not differ between the two ovaries. Subgroup analyses according to the phase of the cycle at the initiation of COS, the type of malignancy, the use of letrozole and the magnitude of the ovarian response did not allow to identify any condition showing a difference in the follicular response between the active and the resting ovaries. In conclusion, follicular growth does not seem to be perturbed by the presence of a dominant follicle or a corpus luteum.
Identifiants
pubmed: 32572130
doi: 10.1038/s41598-020-67151-x
pii: 10.1038/s41598-020-67151-x
pmc: PMC7308302
doi:
Substances chimiques
Letrozole
7LKK855W8I
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
10083Références
Sönmezer, M., Türkçüoğlu, I., Coşkun, U. & Oktay, K. Random-start controlled ovarian hyperstimulation for emergency fertility preservation in letrozole cycles. Fertil Steril. 95, e9–11 (2011).
doi: 10.1016/j.fertnstert.2011.01.030
Oktay, K. et al. Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update. J. Clin. Oncol. 36, 1994–2001 (2018).
doi: 10.1200/JCO.2018.78.1914
Cakmak, H. & Rosen, M. P. Random-start ovarian stimulation in patients with cancer. Curr Opin. Obstet. Gynecol. 27, 215–21 (2015).
doi: 10.1097/GCO.0000000000000180
Danis, R. B., Pereira, N. & Elias, R. T. Random Start Ovarian Stimulation for Oocyte or Embryo Cryopreservation in Women Desiring Fertility Preservation Prior to Gonadotoxic Cancer Therapy. Curr. Pharm. Biotechnol. 18, 609–13 (2017).
doi: 10.2174/1389201018666170808122531
Ortega, I., García-Velasco, J. A. & Pellicer, A. Ovarian manipulation in ART: going beyond physiological standards to provide best clinical outcomes. J. Assist. Reprod. Genet. 35, 1751–62 (2018).
doi: 10.1007/s10815-018-1258-6
Sighinolfi, G., Sunkara, S. K. & La Marca, A. New strategies of ovarian stimulation based on the concept of ovarian follicular waves: From conventional to random and double stimulation. Reprod. Biomed. Online. 37, 489–97 (2018).
doi: 10.1016/j.rbmo.2018.07.006
Mangili, G. et al. Timing should no longer be an obstacle to oocyte cryopreservation in patients with cancer. Tumori. 103, 182–86 (2017).
doi: 10.5301/tj.5000586
Letourneau, J. M. et al. Random start ovarian stimulation for fertility preservation appears unlikely to delay initiation of neoadjuvant chemotherapy for breast cancer. Hum. Reprod. 32, 2123–9 (2017).
doi: 10.1093/humrep/dex276
Moravek, M. B. et al. Long-term outcomes in cancer patients who did or did not pursue fertility preservation. Fertil. Steril. 109, 349–55 (2018).
doi: 10.1016/j.fertnstert.2017.10.029
Nakasuji, T. et al. Random-start ovarian stimulation with aromatase inhibitor for fertility preservation in women with Japanese breast cancer. Reprod. Med. Biol. 18, 167–72 (2018).
doi: 10.1002/rmb2.12263
Wald K, et al. Back-to-back random-start ovarian stimulation prior to chemotherapy to maximize oocyte yield. J. Assist. Reprod. Genet. [Epub ahead of print] 2019.
Sarais, V. et al. Long-acting recombinant follicle-stimulating hormone in random-start ovarian stimulation protocols for fertility preservation in women with cancer. Acta Obstet. Gynecol. Scand. 96, 949–53 (2017).
doi: 10.1111/aogs.13146
Campos, A. P. C., Geber, G. P., Hurtado, R., Sampaio, M. & Geber, S. Ovarian response after random-start controlled ovarian stimulation to cryopreserve oocytes in cancer patients. JBRA Assist. Reprod. 22, 352–54 (2018).
pubmed: 30264947
Muteshi, C., Child, T., Ohuma, E. & Fatum, M. Ovarian response and follow-up outcomes in women diagnosed with cancer having fertility preservation: Comparison of random start and early follicular phase stimulation - cohort study. Eur. J. Obstet. Gynecol. Reprod. Biol. 230, 10–14 (2018).
doi: 10.1016/j.ejogrb.2018.09.007
Rashidi, B. H., Tehrani, E. S. & Ghaffari, F. Ovarian stimulation for emergency fertility preservation in cancer patients: A case series study. Gynecol. Oncol. Rep. 10, 19–21 (2014).
doi: 10.1016/j.gore.2014.08.002
Cavagna, F. et al. Specific protocols of controlled ovarian stimulation for oocyte cryopreservation in breast cancer patients. Curr. Oncol. 25, e527–32 (2018).
doi: 10.3747/co.25.3889
Filippi, F. et al. Fertility preservation in women with malignancies: the accuracy of antral follicle count collected randomly during the menstrual cycle in predicting the number of oocytes retrieved. J. Assist. Reprod. Genet. 36, 569–78 (2019).
doi: 10.1007/s10815-018-1377-0
Jochum, F. et al. Luteal phase stimulation, the future of fertility preservation? Retrospective cohort study of luteal phase versus follicular phase stimulation. J. Gynecol. Obstet. Hum. Reprod. 48, 91–94 (2019).
doi: 10.1016/j.jogoh.2018.11.003
Hamdan, M., Dunselman, G., Li, T. C. & Cheong, Y. The impact of endometrioma on IVF/ICSI outcomes: a systematic review and meta-analysis. Hum. Reprod. Update. 21, 809–25 (2015).
doi: 10.1093/humupd/dmv035
Somigliana, E. et al. Risks of conservative management in women with ovarian endometriomas undergoing IVF. Hum. Reprod. Update. 21, 486–99 (2015).
doi: 10.1093/humupd/dmv012
Devoto, L., Henríquez, S., Kohen, P. & Strauss, J. F. 3rd The significance of estradiol metabolites in human corpus luteum physiology. Steroids. 123, 50–54 (2017).
doi: 10.1016/j.steroids.2017.05.002
Stouffer, R. L., Bishop, C. V., Bogan, R. L., Xu, F. & Hennebold, J. D. Endocrine and local control of the primate corpus luteum. Reprod Biol. 13, 259–271 (2013).
doi: 10.1016/j.repbio.2013.08.002
Knight, P. G. & Glister, C. TGF-beta superfamily members and ovarian follicle development. Reproduction. 132, 191–206 (2006).
doi: 10.1530/rep.1.01074
Ecochard, R. & Gougeon, A. Side of ovulation and cycle characteristics in normally fertile women. Hum. Reprod. 15, 752–5 (2000).
doi: 10.1093/humrep/15.4.752
Rowan, K. et al. Corpus luteum across the first trimester: size and laterality as observed by ultrasound. Fertil. Steril. 90, 1844–7 (2008).
doi: 10.1016/j.fertnstert.2007.09.022
Cobo, A., García-Velasco, J., Domingo, J., Pellicer, A. & Remohí, J. Elective and Onco-fertility preservation: factors related to IVF outcomes. Hum. Reprod. 33, 2222–31 (2018).
doi: 10.1093/humrep/dey321